@kensiejames I appreciate your post about the benefits of Zometa for early-stage breast cancer. Even though that's not a ton of information, it's more information than any of my doctors have offered! So far, when pressed by me as to whether the Zometa is primarily for bone health (preventing fractures) or to offer protection against possible cancer spreading to the bones, they have emphasized that it's to prevent fracture more than to prevent cancer spread. Had I declined Zometa, though, perhaps they would have emphasized the cancer spread prevention.

Your information prompted me to look a bit further. Google AI's main statement echoes your statement. There is mention of Zometa altering the bone microenvironment which makes the growth of cancer cells less likely.

Google AI also states that ideally one would start it within 3 months after surgery, which I did not do. But it also goes on to add "However, studies indicate that it does not improve survival rates more than 2 years of treatment compared to longer durations." The sources for this statement are the National Cancer Institute and breastcancer.org. The statement is somewhat vague and one would need to track down the original studies to really understand their findings.

These same sources are referred to behind this:
The long-term implications of using Zometa (zoledronic acid) in breast cancer patients include a reduced risk of breast cancer recurrence in the bone and improved survival rates among postmenopausal women. However, there are potential side effects, such as osteonecrosis of the jaw and kidney toxicity, that patients should be aware of.